SCM
CTMX icon

Stonepine Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Stonepine Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$940K Buy
+200,000
New +$1.02M 0.38% 38

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stonepine Capital Management's CTMX Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 200,000 shares worth $940K. The stake represents 0.38% of the portfolio and ranks #39 among its holdings. This is a return to the name: Stonepine Capital Management previously reported a position in CTMX as recently as Q3 2025.

Stonepine Capital Management first reported a position in CTMX in Q3 2025 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Stonepine Capital Management held 200,000 shares of CytomX Therapeutics worth $940K as of Q1 2026.
  • CytomX Therapeutics was a new Stonepine Capital Management position in Q1 2026.
  • CytomX Therapeutics made up 0.38% of Stonepine Capital Management's portfolio in Q1 2026, its #39 holding.
  • Stonepine Capital Management first reported a position in CytomX Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.